ScinoPharm Taiwan Ltd
ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, the America, and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptide… Read more
ScinoPharm Taiwan Ltd (1789) - Total Assets
Latest total assets as of September 2025: NT$12.31 Billion TWD
Based on the latest financial reports, ScinoPharm Taiwan Ltd (1789) holds total assets worth NT$12.31 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ScinoPharm Taiwan Ltd - Total Assets Trend (2007–2024)
This chart illustrates how ScinoPharm Taiwan Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ScinoPharm Taiwan Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
ScinoPharm Taiwan Ltd's total assets of NT$12.31 Billion consist of 55.3% current assets and 44.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 34.9% |
| Accounts Receivable | NT$654.19 Million | 5.5% |
| Inventory | NT$1.67 Billion | 14.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$17.13 Million | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how ScinoPharm Taiwan Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ScinoPharm Taiwan Ltd's current assets represent 55.3% of total assets in 2024, an increase from 38.0% in 2007.
- Cash Position: Cash and equivalents constituted 34.9% of total assets in 2024, up from 0.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 14.0% of total assets.
ScinoPharm Taiwan Ltd Competitors by Total Assets
Key competitors of ScinoPharm Taiwan Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
ScinoPharm Taiwan Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ScinoPharm Taiwan Ltd generates 0.29x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, ScinoPharm Taiwan Ltd generates $ 2.84 in net profit.
ScinoPharm Taiwan Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.85 | 9.35 | 8.62 |
| Quick Ratio | 5.09 | 6.64 | 6.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$4.72 Billion | NT$ 5.79 Billion | NT$ 5.23 Billion |
ScinoPharm Taiwan Ltd - Advanced Valuation Insights
This section examines the relationship between ScinoPharm Taiwan Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.56 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 1.9% |
| Total Assets | NT$11.94 Billion |
| Market Capitalization | $180.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values ScinoPharm Taiwan Ltd's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ScinoPharm Taiwan Ltd's assets grew by 1.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ScinoPharm Taiwan Ltd (2007–2024)
The table below shows the annual total assets of ScinoPharm Taiwan Ltd from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$11.94 Billion | +1.89% |
| 2023-12-31 | NT$11.72 Billion | -1.59% |
| 2022-12-31 | NT$11.91 Billion | +1.88% |
| 2021-12-31 | NT$11.69 Billion | -1.31% |
| 2020-12-31 | NT$11.85 Billion | +1.47% |
| 2019-12-31 | NT$11.67 Billion | -7.07% |
| 2018-12-31 | NT$12.56 Billion | -1.09% |
| 2017-12-31 | NT$12.70 Billion | -0.64% |
| 2016-12-31 | NT$12.78 Billion | +4.59% |
| 2015-12-31 | NT$12.22 Billion | +7.47% |
| 2014-12-31 | NT$11.37 Billion | -0.98% |
| 2013-12-31 | NT$11.48 Billion | +11.07% |
| 2012-12-31 | NT$10.34 Billion | +9.07% |
| 2011-12-31 | NT$9.48 Billion | +29.90% |
| 2010-12-31 | NT$7.30 Billion | +25.31% |
| 2009-12-31 | NT$5.82 Billion | +1.08% |
| 2008-12-31 | NT$5.76 Billion | +2.21% |
| 2007-12-31 | NT$5.64 Billion | -- |